@article {7703,
	title = {Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children.},
	journal = {Int J Hematol},
	volume = {102},
	year = {2015},
	month = {2015 Nov},
	pages = {626-32},
	abstract = {<p>The outcome of romiplostim for secondary failure of platelet recovery (SFPR) was investigated in children who had undergone hematopoietic stem cell transplantation (HSCT). Seven transfusion-dependent pediatric patients (median age 11~years), with platelet counts below 10~{\texttimes}~10(9)/L, received four weekly doses of subcutaneous romiplostim to treat SFPR developed after HSCT. All patients, except one (patient 4), became platelet transfusion-independent in the second week from the beginning of treatment and no patient needed to discontinue drug treatment because of adverse events. Romiplostim could represent a beneficial first-line treatment, but further studies are required.</p>},
	issn = {1865-3774},
	doi = {10.1007/s12185-015-1821-1},
	author = {Maximova, Natalia and Zanon, D and Rovere, F and Maestro, A and Schillani, G and Paparazzo, R}
}
